Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI eye exam could spot diabetes blindness before it starts

NCT ID NCT07378891

Diagnosis Sponsor: University Hospital Tuebingen Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only This study
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is testing whether an artificial intelligence (AI) program can spot early signs of diabetic retinopathy—a condition that can lead to blindness—in people with prediabetes and diabetes. Researchers will take pictures of the retina and use the AI to analyze them. The goal is to see if this technology can catch eye damage earlier than current methods, potentially helping people get treatment sooner.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could lead to a simple, AI-powered eye test that catches diabetes-related eye damage early, potentially preventing vision loss.
What could go wrong
This is a small, early-stage study (100 participants) focused on testing the AI's accuracy, not on treatment. The AI may not work as well in larger, more diverse groups.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 100 people

The number the study aims to enrol. It can still change while the study runs.

Started

Dec 2025

Expected to finish

Dec 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Diabetic patients in the University Hospital Tuebingen, volunteers with prediabetes

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Voluntary adults * Aged between 18 and 80 years * Understanding of the study explanations and instructions * Prediabetes (defined by elevated fasting glucose 100-125 mg/dL and/or 2-hour glucose in the oral glucose tolerance test of 140-199 mg/dL and/or HbA1c of 5.7-6.4%) * manifest diabetes (all types of diabetes according to Ahlqvist) Exclusion Criteria: * participants unable to give consent * Those who do not agree to be informed about incidentally detected pathological findings * Uncontrolled arterial hypertension (Stage III) despite multiple antihypertensive medications * Eye diseases that impair the interpretability of the fundus examination

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Diabetes (DM) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

diabetes mellitus diabetic retinopathy prediabetes syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Diabetes (DM) Prediabetes

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • University Hospital Tuebingen, Dep. Diabetology

    Tübingen, 72076, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.